AbbVie’s Venclexta Fails In Combo AML Trial

Pfizer’s Daurismo May Benefit From Venclexta’s VIALE-C Setback

 
• By Sten Stovall
  
AML
Venclexta missed VIALE-C Phase III endpoints in acute myeloid leukemia • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D